STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the contemporaneous WHO-recommended regimen. This regimen included moxifloxacin and clofazimine, known to cause QT prolongation, and severe prolongation was more common on the Short regimen. This study investigated risk factors for QT prolongation with the Short regimen.
Recent Abstracts
Relatório de Atividades 2025 – Brasil
Mais Dados Mais Saúde – Percepções da população brasileira sobre fatores de risco…
What Primary Care Records Reveal About Cancer Signs and Symptoms
O que os prontuários da atenção primária revelam sobre sinais e sintomas de…
CRVS Performance Measurement and Monitoring Resource Kit
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council
The invisible pain: Gaps in Brazil’s public health system data on Menstrual and…
Exploring the Interface Between Birth Registration and Citizenship Determination: A Scoping Study in…
A dor invisível: lacunas nos dados do SUS sobre dor menstrual e pélvica
Catalyzing Support for CRVS Improvement – Examples from the Data for Health Initiative